Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: A review of chemistry, cellular, molecular, and preclinical features

BioFactors

Volumn 43, Issue 3, 2017, Pages 331-346

  Teymouri, Manouchehr ^a   Pirro, Matteo ^b   Johnston, Thomas P ^c   Sahebkar, Amirhosein ^d  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

apoptosis; benzo(a)pyrene; cervical cancer; curcumin; human papilloma virus

Indexed keywords

BENZO[A]PYRENE; CURCUMIN; CYCLOOXYGENASE 2; ESTRADIOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 13; PRB PROTEIN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; PROTEIN BAX; RETINOBLASTOMA PROTEIN;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CONDYLOMA ACUMINATUM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SMOKING; UTERINE CERVIX CANCER; VIRAL CLEARANCE; VIRUS CARCINOGENESIS; WART VIRUS; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPLICATION; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PATHOGENICITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; UTERINE CERVIX TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BCL-2-ASSOCIATED X PROTEIN; CURCUMIN; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REACTIVE OXYGEN SPECIES; RETINOBLASTOMA PROTEIN; RISK FACTORS; SIGNAL TRANSDUCTION; SMOKING; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 85006176226     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1344     Document Type: Review

References (127)

1. McGraw, S. L., and Ferrante, J. M. (2014) Update on prevention and screening of cervical cancer. World J. Clin. Oncol., 5, 744–752.
2. Münger, K., Baldwin, A., Edwards, K. M., Hayakawa, H., Nguyen, C. L., et al. (2004) Mechanisms of human papillomavirus-induced oncogenesis. J. Virol., 78, 11451–11460.
3. Lim, C. B., Ky, N., Ng, H. M., Hamza, M. S., and Zhao, Y. (2010) Curcuma wenyujin extract induces apoptosis and inhibits proliferation of human cervical cancer cells in vitro and in vivo. Integr. Cancer Ther., 9, 36–49.
4. Münger, K., Scheffner, M., Huibregtse, J., and Howley, P. (1991) Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv., 12, 197–217.
5. Alazawi, W., Pett, M., Arch, B., Scott, L., Freeman, T., et al. (2002) Changes in cervical keratinocyte gene expression associated with integration of human papillomavirus 16. Cancer Res., 62, 6959–6965.
6. Durst, M., Gallahan, D., Jay, G., and Rhim, J. S. (1989) Glucocorticoid-enhanced neoplastic transformation of human keratinocytes by human papillomavirus type 16 and an activated ras oncogene. Virology, 173, 767–771.
7. Duensing, S., and Münger, K. (2004) Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int. J. Cancer, 109, 157–162.
8. Pfaendler, K. S., and Tewari, K. S. (2016) Changing paradigms in the systemic treatment of advanced cervical cancer. Am. J. Obstet. Gynecol., 214, 22–30.
9. Zanetta, G., Fei, F., and Mangioni, C. (2000) Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza. Semin. Oncol., 23–27.
10. Debata, P. R., Castellanos, M. R., Fata, J. E., Baggett, S., Rajupet, S., et al. (2013) A novel curcumin-based vaginal cream Vacurin selectively eliminates apposed human cervical cancer cells. Gynecol. Oncol., 129, 145–153.
11. Kohn, E. C., Sarosy, G., Bicher, A., Link, C., Christian, M., et al. (1994) Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J. Natl. Cancer Inst., 86, 18–24.
12. Akhtari, J., Rezayat, S. M., Teymouri, M., Alavizadeh, S. H., Gheybi, F., et al. (2016) Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors. Int. J. Pharm., 505, 89–95.
13. Singh, M., and Singh, N. (2009) Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells. Mol. Cell. Biochem., 325, 107–119.
14. Roy, M., and Mukherjee, S. (2014) Reversal of resistance towards cisplatin by curcumin in cervical cancer cells. Asian Pac. J. Cancer Prev., 15, 1403–1410.
15. Sreekanth, C. N., Bava, S. V., Sreekumar, E., and Anto, R. J. (2011) Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene, 30, 3139–3152.
16. Kuo, M. T. (2009) Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxid. Redox Signal, 11, 99–133.
17. Song, W., Jiang, R., and Zhao, C. M. (2012) Role of integrin-linked kinase in multi-drug resistance of human gastric carcinoma SGC7901/DDP cells. Asian Pac. J. Cancer Prev., 13, 5619–5625.
18. Aggarwal, B. B., Shishodia, S., Takada, Y., Banerjee, S., Newman, R. A., et al. (2005) Curcumin suppresses the paclitaxel-induced nuclear factor-κB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin. Cancer Res., 11, 7490–7498.
19. Javvadi, P., Segan, A. T., Tuttle, S. W., and Koumenis, C. (2008) The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol. Pharmacol., 73, 1491–1501.
20. Dang, Y. P., Yuan, X. Y., Tian, R., Li, D. G., and Liu, W. (2015) Curcumin improves the paclitaxel induced apoptosis of HPV positive human cervical cancer cells via the NF κB p53 caspase 3 pathway. Exp. Ther. Med., 9, 1470–1476.
21. Anand, P., Thomas, S., Kumar, A., Kunnumakkaram, B., Sundaram, C., et al. (2008) Antioxidant, anti-inflammatory, anticancer, anticarcinogenic, antidiabetic and neuroprotective effects of curcuminanalogues (congeners) made by man and mother nature. Biochem. Pharmacol., 76, 1590–1611.
22. Singh, A. K., and Misra, K. (2013) Human papilloma virus 16 e6 protein as a target for curcuminoids, curcumin conjugates and congeners for chemoprevention of oral and cervical cancers. Interdiscip. Sci., 5, 112–118.
23. Paulraj, F., Abas, F., Lajis, N. H., Othman, I., Hassan, S. S., et al. (2015) The curcumin analogue 1,5-bis(2-hydroxyphenyl)−1,4-pentadiene-3-one induces apoptosis and downregulates E6 and E7 oncogene expression in HPV16 and HPV18-infected cervical cancer cells. Molecules, 20, 11830–11860.
24. Panahi, Y., Sahebkar, A., Parvin, S., and Saadat, A. (2012) A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann. Clin. Biochem., 49, 580–588.
25. Panahi, Y., Saadat, A., Beiraghdar, F., and Sahebkar, A. (2014) Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother. Res., 28, 1461–1467.
26. Sahebkar, A. (2014) Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother. Res., 28, 633–642.
27. Panahi, Y., Ghanei, M., Bashiri, S., Hajihashemi, A., and Sahebkar, A. (2015) Short-term Curcuminoid Supplementation for Chronic Pulmonary Complications due to Sulfur Mustard Intoxication: Positive Results of a Randomized Double-blind Placebo-controlled Trial. Drug Res., 65, 567–573.
28. Panahi, Y., Hosseini, M. S., Khalili, N., Naimi, E., Majeed, M., et al. (2015) Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis. Clin. Nutr., 34, 1101–1108.
29. Sahebkar, A., Mohammadi, A., Atabati, A., Rahiman, S., Tavallaie, S., et al. (2013) Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother. Res., 27, 1883–1888.
30. Panahi, Y., Saadat, A., Beiraghdar, F., Hosseini Nouzari, S. M., Jalalian, H. R., et al. (2014) Antioxidant effects of bioavailability-enhanced curcuminoids in patients with solid tumors: A randomized double-blind placebo-controlled trial. J. Funct. Foods, 6, 615–622.
31. Sahebkar, A., Serban, M. C., Ursoniu, S., and Banach, M. (2015) Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials. J. Funct. Foods, 18, 898–909.
32. Panahi, Y., Alishiri, G. H., Parvin, S., and Sahebkar, A. (2016) Mitigation of systemic oxidative stress by curcuminoids in osteoarthritis: results of a randomized controlled trial. J. Diet. Suppl., 13, 209–220.
33. Panahi, Y., Ghanei, M., Hajhashemi, A., and Sahebkar, A. (2016) Effects of curcuminoids-piperine combination on systemic oxidative stress, clinical symptoms and quality of life in subjects with chronic pulmonary complications due to sulfur mustard: a randomized controlled trial. J. Diet. Suppl., 13, 93–105.
34. Panahi, Y., Rahimnia, A. R., Sharafi, M., Alishiri, G., Saburi, A., et al. (2014) Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother. Res., 28, 1625–1631.
35. Iranshahi, M., Sahebkar, A., Takasaki, M., Konoshima, T., and Tokuda, H. (2009) Cancer chemopreventive activity of the prenylated coumarin, umbelliprenin, in vivo. Eur.J. Cancer Prevent., 18, 412–415.
36. Iranshahi, M., Sahebkar, A., Hosseini, S. T., Takasaki, M., Konoshima, T., et al. (2010) Cancer chemopreventive activity of diversin from Ferula diversivittata in vitro and in vivo. Phytomedicine, 17, 269–273.
37. Mirzaei, H., Naseri, G., Rezaee, R., Mohammadi, M., Banikazemi, Z., et al. Curcumin: a new candidate for melanoma therapy? Int. J. Cancer, 139, 1683–1695.
38. Momtazi, A., and Sahebkar, A. A. Difluorinated curcumin: a promising curcumin analogue with improved anti-tumor activity and pharmacokinetic profile. Curr. Pharm. Des., 22, 4386–4397.
39. Momtazi, A. A., Shahabipour, F., Khatibi, S., Johnston, T. P., Pirro, M., et al. (2016) Curcumin as a MicroRNA regulator in cancer: a review. Rev. Physiol. Biochem. Pharmacol., 171, 1–38.
40. Panahi, Y., Khalili, N., Hosseini, M. S., Abbasinazari, M., Sahebkar, A. (2014) Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Ther Med., 22, 851–857.
41. Mohammadi, A., Sahebkar, A., Iranshahi, M., Amini, M., Khojasteh, R., et al. (2013) Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother. Res., 27, 374–379.
42. Sahebkar, A. (2013) Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors, 39, 197–208.
43. Sahebkar, A. (2014) Curcuminoids for the management of hypertriglyceridaemia. Nat. Rev. Cardiol., 11, 123.
44. Sahebkar, A. (2014) Low-density lipoprotein is a potential target for curcumin: novel mechanistic insights. Basic Clin. Pharmacol. Toxicol., 114, 437–438.
45. Sahebkar, A., Chew, G. T., and Watts, G. F. (2014) Recent advances in pharmacotherapy for hypertriglyceridemia. Prog. Lipid Res., 56, 47–66.
46. Sahebkar, A. (2015) The promise of curcumin-phosphatidylcholine complex for cardiometabolic diseases: more than just 'more curcumin'. Nat. Prod. Res., 29, 392–393.
47. Sahebkar, A. (2015) Dual effect of curcumin in preventing atherosclerosis: the potential role of pro-oxidant-antioxidant mechanisms. Nat. Prod. Res., 29, 491–492.
48. Panahi, Y., Kianpour, P., Mohtashami, R., Jafari, R., Simental-Mendia, L. E., et al. (2016) Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial. J. Cardiovasc. Pharmacol., 68, 223–229.
49. RahmaniAsgary, S., Askari, S., Keshvari, G., Hatamipour, M., Feizi, M., et al. (2016) Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial. Phytother. Res., 30, 1540–1548.
50. Esmaily, H., Sahebkar, A., Iranshahi, M., Ganjali, S., Mohammadi, A., et al. (2015) An investigation of the effects of curcumin on anxiety and depression in obese individuals: a randomized controlled trial. Chin. J. Integr. Med., 21, 332–338.
51. Panahi, Y., Badeli, R., Karami, G. R., and Sahebkar, A. (2015) Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother. Res., 29, 17–21.
52. Panahi, Y., Hosseini, M., Khalili, S., Naimi, N. E., Soflaei, S., et al. (2016) Effects of supplementation with curcumin on serum adipokine concentrations: a randomized controlled trial. Nutrition, 32, 1116–1122.
53. Panahi, Y., Sahebkar, A., Amiri, M., Davoudi, S. M., Beiraghdar, F., et al. (2012) Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br. J. Nutr., 108, 1272–1279.
54. Sahebkar, A. (2010) Molecular mechanisms for curcumin benefits against ischemic injury. Fertil. Steril., 94, e75–e76. author reply e77.
55. Ghosh, S., Banerjee, S., and Sil, P. C. (2015) The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: a recent update. Food Chem. Toxicol., 83, 111–124.
56. Nabavi, S. F., Thiagarajan, R., Rastrelli, L., Daglia, M., Sobarzo-Sanchez, E., et al. (2015) Curcumin: a natural product for diabetes and its complications. Curr. Top. Med. Chem., 15, 2445–2455.
57. Ganjali, S., Sahebkar, A., Mahdipour, E., Jamialahmadi, K., Torabi, S., et al. (2014) Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial. ScientificWorldJournal, 2014, 898361.
58. Sahebkar, A., Cicero, A. F., Simental-Mendia, L. E., Aggarwal, B. B., and Gupta, S. C. (2016) Curcumin downregulates human tumor necrosis factor-alpha levels: a systematic review and meta-analysis ofrandomized controlled trials. Pharmacol. Res., 107, 234–242.
59. Momtazi, A. A., Derosa, G., Maffioli, P., Banach, M., and Sahebkar, A. (2016) Role of microRNAs in the Therapeutic Effects of Curcumin in Non-Cancer Diseases. Mol. Diagn. Ther., 20, 335–345.
60. Sahebkar, A. (2016) Autophagic activation: a key piece of the puzzle for the curcumin-associated cognitive enhancement? J. Psychopharmacol., 30, 93–94.
61. Shakeri, A., and Sahebkar, A. (2016) Optimized curcumin formulations for the treatment of Alzheimer's disease: a patent evaluation. J. Neurosci. Res., 94, 111–113.
62. Sahebkar, A., and Henrotin, Y. (2016) Analgesic Efficacy and Safety of Curcuminoids in Clinical Practice: a Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pain Med., 17, 1192–1202.
63. Basu, P., Dutta, S., Begum, R., Mittal, S., Dutta, P. D., et al. (2013) Clearance of cervical human papillomavirus infection by topical application of curcumin and curcumin containing polyherbal cream: a phase II randomized controlled study. Asian Pac. J. Cancer Prev., 14, 5753–5759.
64. Mishra, A., and Das, B. C. (2015) Curcumin as an anti-human papillomavirus and anti-cancer compound. Future Oncol., 11, 2487–2490.
65. Priyadarsini, K. I. (2014) The chemistry of curcumin: from extraction to therapeutic agent. Molecules, 19, 20091–20112.
66. LeeKim, K., and Ma, Y. J. (2013) Separation and identification of curcuminoids from Asian turmeric (Curcuma longa L.) using RP-HPLC and LC-MS. Asian J. Chem., 25, 909.
67. Ali, I., Haque, A., and Saleem, K. (2014) Separation and identification of curcuminoids in turmeric powder by HPLC using phenyl column. Anal. Methods, 6, 2526–2536.
68. Youns, M., and Fathy, G. M. (2013) Upregulation of extrinsic apoptotic pathway in curcumin-mediated antiproliferative effect on human pancreatic carcinogenesis. J. Cell. Biochem., 114, 2654–2665.
69. Priyadarsini, K. I. (2009) Photophysics, photochemistry and photobiology of curcumin: Studies from organic solutions, bio-mimetics and living cells. J. Photochem. Photobiol. C, 10, 81–95.
70. Kumar, D., Basu, S., Parija, L., Rout, D., Manna, S., et al. (2016) Curcumin and Ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells. Biomed. Pharmacother., 81, 31–37.
71. Sharma, O. (1976) Antioxidant activity of curcumin and related compounds. Biochem. Pharmacol., 25, 1811–1812.
72. Naksuriya, O., Okonogi, S., Schiffelers, R. M., and Hennink, W. E. (2014) Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials, 35, 3365–3383.
73. Ahmad, M. Z., Alkahtani, S., Akhter, A. S., Ahmad, F., Ahmad, J. J., et al. (2015) Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art. J. Drug Target, 1–21.
74. Nakagawa, K., Zingg, J. M., Kim, S. H., Thomas, M. J., Dolnikowski, G. G., et al. (2014) Differential cellular uptake and metabolism of curcuminoids in monocytes/macrophages: regulatory effects on lipid accumulation. Br. J. Nutr., 112, 8–14.
75. Balstad, T. R., Carlsen, H., Myhrstad, M. C., Kolberg, M., Reiersen, H., et al. (2011) Coffee, broccoli and spices are strong inducers of electrophile response element-dependent transcription in vitro and in vivo - studies in electrophile response element transgenic mice. Mol. Nutr. Food Res., 55, 185–197.
76. Dehn, D., Torkko, K. C., and Shroyer, K. R. (2007) Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer Cytopathol., 111, 1–14.
77. Wittekindt, C., Gultekin, E., Weissenborn, S. J., Dienes, H. P., Pfister, H. J., et al. (2005) Expression of p16 protein is associated with human papillomavirus status in tonsillar carcinomas and has implications on survival. Adv. Otorhinolaryngol., 62, 72–80.
78. Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., et al. (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol., 6, 271–278.
79. Stanley, M. (2010) Potential mechanisms for HPV vaccine-induced long-term protection. Gynecol. Oncol., 118, S2–S7.
80. Cheng, A. L., Hsu, C. H., Lin, J. K., Hsu, M. M., Ho, Y. F., et al. (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res., 21, 2895–2900.
81. Maher, D. M., Bell, M. C., O'Donnell, E. A., Gupta, B. K., Jaggi, M., et al. (2011) Curcumin suppresses human papillomavirus oncoproteins, restores p53, rb, and ptpn13 proteins and inhibits benzo[a]pyrene-induced upregulation of HPV E7. Mol. Carcinog., 50, 47–57.
82. Prusty, B. K., and Das, B. C. (2005) Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. Int. J. Cancer, 113, 951–960.
83. Scheffner, M., Huibregtse, J. M., Vierstra, R. D., and Howley, P. M. (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell, 75, 495–505.
84. Nuss Parker, J., Zhao, W., Askins, K. J., Broker, T. R., and Chow, L. T. (1997) Mutational analyses of differentiation-dependent human papillomavirus type 18 enhancer elements in epithelial raft cultures of neonatal foreskin keratinocytes. Cell Growth Differ., 8, 751–762.
85. Chou, C. W., Wu, M. S., Huang, W. C., and Chen, C. C. (2011) HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PloS One, 6, e18087.
86. Shiomi, T., and Okada, Y. (2003) MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev., 22, 145–152.
87. Egeblad, M., and Werb, Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2, 161–174.
88. Han, Y. P., Tuan, T. L., Wu, H., Hughes, M., and Garner, W. L. (2001) TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa) B mediated induction of MT1-MMP. J. Cell Sci., 114, 131–139.
89. Thacker, P. C., and Karunagaran, D. (2015) Curcumin and emodin down-regulate TGF-β signaling pathway in human cervical cancer cells. PLoS One, 10,
90. Xu, F., Mu, X., and Zhao, J. (2009) Effects of curcumin on invasion and metastasis in the human cervical cancer cells Caski. Chin. J. Cancer Res., 21, 159–162.
91. Divya, C. S., and Pillai, M. R. (2006) Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis. Mol. Carcinog., 45, 320–332.
92. Beg, A. A., and Baltimore, D. (1996) An essential role for NF-κB in preventing TNF-α-induced cell death. Science, 274, 782–784.
93. Madden, K., Flowers, L., Salani, R., Horowitz, I., Logan, S., et al. (2009) Proteomics-based approach to elucidate the mechanism of antitumor effect of curcumin in cervical cancer. Prostaglandins Leukot. Essent. Fatty Acids, 80, 9–18.
94. Zaman, M. S., Chauhan, N., Yallapu, M. M., Gara, R. K., Maher, D. M., et al. (2016) Curcumin Nanoformulation for Cervical Cancer Treatment. Sci. Rep., 6,
95. Yoysungnoen-Chintana, P., Bhattarakosol, P., and Patumraj, S. (2014) Antitumor and antiangiogenic activities of curcumin in cervical cancer xenografts in nude mice. Biomed. Res. Int., 2014, 1–12.
96. Kim, B., Kim, H. S., Jung, E. J., Lee, J. Y., Tsang, B. K., et al. (2015) Curcumin induces ER stress-mediated apoptosis through selective generation of reactive oxygen species in cervical cancer cells. Mol. Carcinog., 55, 918–928.
97. Tabas, I., and Ron, D. (2011) Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat. Cell. Biol., 13, 184–190.
98. Wang, W. A., Groenendyk, J., and Michalak, M. (2014) Endoplasmic reticulum stress associated responses in cancer. Biochim. Biophys. Acta, 1843, 2143–2149.
99. Trachootham, D., Alexandre, J., and Huang, P. (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov., 8, 579–591.
100. Cai, W., Zhang, B., Duan, D., Wu, J., and Fang, J. (2012) Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells. Toxicol. Appl. Pharmacol., 262, 341–348.
101. Moreno, V., Bosch, F. X., Muñoz, N., Meijer, C. J., Shah, K. V., et al. (2002) Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet, 359, 1085–1092.
102. Muñoz, N., Franceschi, S., Bosetti, C., Moreno, V., Herrero, R., et al. (2002) Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet, 359, 1093–1101.
103. Castellsagué, X., Díaz, M., De Sanjosé, S., Muñoz, N., Herrero, R., et al. (2006) International Agency for Research on Cancer Multicenter Cervical Cancer Study Group Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J. Natl. Cancer Inst., 98, 303–315.
104. Vishvakarma, N. K., Kumar, A., and Singh, S. M. (2011) Role of curcumin-dependent modulation of tumor microenvironment of a murine T cell lymphoma in altered regulation of tumor cell survival. Toxicol. Appl. Pharmacol., 252, 298–306.
105. Lu, H. F., Yang, J. S., Lai, K. C., Hsu, S. C., Hsueh, S. C., et al. (2009) Curcumin-induced DNA damage and inhibited DNA repair genes expressions in mouse–rat hybrid retina ganglion cells (N18). Neurochem. Res., 34, 1491–1497.
106. Lewinska, A., Adamczyk, J., Pajak, J., Stoklosa, S., Kubis, B., et al. (2014) Curcumin-mediated decrease in the expression of nucleolar organizer regions in cervical cancer (HeLa) cells. Mutat. Res. Genet. Toxicol. Environ. Mutagen., 771, 43–52.
107. Liu, E., Wu, J., Cao, W., Zhang, J., Liu, W., et al. (2007) Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J. Neurooncol., 85, 263–270.
108. Mosieniak, G., Adamowicz, M., Alster, O., Jaskowiak, H., Szczepankiewicz, A. A., et al. (2012) Curcumin induces permanent growth arrest of human colon cancer cells: link between senescence and autophagy. Mech. Ageing Dev., 133, 444–455.
109. Mayer, C., Bierhoff, H., and Grummt, I. (2005) The nucleolus as a stress sensor: JNK2 inactivates the transcription factor TIF-IA and down-regulates rRNA synthesis. Genes Dev., 19, 933–941.
110. Liu, Z., Xie, Z., Jones, W., Pavlovicz, R. E., Liu, S., et al. (2009) Curcumin is a potent DNA hypomethylation agent. Bioorg. Med. Chem. Lett., 19, 706–709.
111. Medina-Franco, J. L., López-Vallejo, F., Kuck, D., and Lyko, F. (2011) Natural products as DNA methyltransferase inhibitors: a computer-aided discovery approach. Mol. Divers., 15, 293–304.
112. López-Lázaro, M., Willmore, E., Jobson, A., Gilroy, K. L., Curtis, H., et al. (2007) Curcumin Induces High Levels of Topoisomerase I− and II− DNA Complexes in K562 Leukemia Cells. J. Nat. Prod., 70, 1884–1888.
113. López-Lázaro, M. (2008) Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol. Nutr. Food Res., 52, S103–S127.
114. Lee, W. H., Loo, C. Y., Young, P. M., Traini, D., Mason, R. S., et al. (2014) Recent advances in curcumin nanoformulation for cancer therapy. Expert Opin. Drug Deliv., 11, 1183–1201.
115. Anand, P., Kunnumakkara, A. B., Newman, R. A., and Aggarwal, B. B. (2007) Bioavailability of curcumin: problems and promises. Mol. Pharm., 4, 807–818.
116. Zhao, J., Zhao, Y., Zhang, Y., and Chen, W. (2007) Anti-tumor effect of curcumin on human cervical carcinoma HeLa cells in vitro and in vivo. Chin. J. Cancer Res., 19, 32–36.
117. Kuttan, R., Bhanumathy, P., Nirmala, K., and George, M. (1985) Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett., 29, 197–202.
118. Mishra, S., Narain, U., Mishra, R., and Misra, K. (2005) Design, development and synthesis of mixed bioconjugates of piperic acid–glycine, curcumin–glycine/alanine and curcumin–glycine–piperic acid and their antibacterial and antifungal properties. Bioorg. Med. Chem., 13, 1477–1486.
119. Dinda, A. K., Prashant, C. K., Naqvi, S., Unnithan, J., Samim, M., et al. (2012) Curcumin loaded organically modified silica (ORMOSIL) nanoparticle; a novel agent for cancer therapy. Int. J. Nanotechnol., 9, 862–871.
120. Zheng, M., Liu, S., Guan, X., and Xie, Z. (2015) One-Step Synthesis of Nanoscale Zeolitic Imidazolate Frameworks with High Curcumin Loading for Treatment of Cervical Cancer. ACS Appl. Mater. Interfaces, 7, 22181–22187.
121. Estrella, V., Chen, T., Lloyd, M., Wojtkowiak, J., Cornnell, H. H., et al. (2013) Acidity generated by the tumor microenvironment drives local invasion. Cancer Res., 73, 1524–1535.
122. Carr, K. R., Ioffe, Y. J., Filippova, M., Duerksen-Hughes, P., and Chan, P. J. (2015) Combined ultrasound-curcumin treatment of human cervical cancer cells. Eur. J. Obstet. Gynecol. Reprod. Biol., 193, 96–101.
123. Parvathy, K., Negi, P., and Srinivas, P. (2010) Curcumin–amino acid conjugates: synthesis, antioxidant and antimutagenic attributes. Food Chem., 120, 523–530.
124. Jin, D., Park, K. W., Lee, J. H., Song, K., Kim, J. G., et al. (2011) The selective immobilization of curcumin onto the internal surface of mesoporous hollow silica particles by covalent bonding and its controlled release. J. Mater. Chem., 21, 3641–3645.
125. Yallapu, M. M., Othman, S. F., Curtis, E. T., Chauhan, N., Bauer, N. A., et al. (2012) Curcumin loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. Cancer Res., 72, 2893–2893.
126. Singh, D. K., Jagannathan, R., Khandelwal, P., Abraham, P. M., and Poddar, P. (2013) In situ synthesis and surface functionalization of gold nanoparticles with curcumin and their antioxidant properties: an experimental and density functional theory investigation. Nanoscale, 5, 1882–1893.
127. Chen, W., Xu, N., Xu, L., Wang, L., Li, Z., et al. (2010) Multifunctional magnetoplasmonic nanoparticle assemblies for cancer therapy and diagnostics (theranostics). Macromol. Rapid Commun., 31, 228–236.